Cover Image
市場調查報告書

PharmaSphere:北美的醫藥品市場的參與策略

PharmaSphere: North American Market Access Strategy

出版商 GlobalData 商品編碼 333930
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
PharmaSphere:北美的醫藥品市場的參與策略 PharmaSphere: North American Market Access Strategy
出版日期: 2015年06月01日 內容資訊: 英文 100 Pages
簡介

本報告提供美國、加拿大、墨西哥的醫藥品市場環境的相關調查,各國的市場規模的變化與預測,法律制度,健康保險與醫療保險制度,藥價制度,償付制度,商業環境比較分析等,市場進入時的重要事項彙整。

第1章 目錄

第2章 簡介

第3章 市場進入的方針發展

  • 市場進入的主要概念
    • 參照價格制度
  • 醫療技術評估 (ETA:Health Technology Assessments)
    • 藥物經濟學的利用

第4章 美國

  • 醫藥品市場
    • 市場規模、預測
    • 市場區隔、疾病領域
  • 健康保險、醫療保險
    • 管理護理 (管理型醫療)
    • 美國政府的健康保險
    • 兒童醫療保險計劃
  • 法律制度
    • 醫療保險改革法 (ACA) 的實施
    • 健康保險、醫療保險市場
  • 藥價設定
    • 藥價制度
    • 資金的類型
  • 償付
    • AMCP (Academy of Managed Care Pharmacy) 指導格式
    • 醫療保險保險制度

第5章 加拿大

  • 醫藥品市場
    • 市場規模、預測
    • 市場區隔、疾病領域
  • 健康保險、醫療保險
    • 公共保險
    • 民間保險
  • 法律制度
    • 加拿大保健法 (Canada Health Act)
    • NPS (National Pharmaceuticals Strategy)
  • 藥價設定
    • 藥價設定制度
    • 專利醫藥品的價格趨勢
  • 償付
    • 償付制度

第6章 墨西哥

  • 醫藥品市場
    • 市場規模、預測s
    • 市場區隔、疾病領域
  • 健康保險、醫療保險
    • 公共保險
    • 民間保險
  • 法律制度
    • COFEPRIS
  • 藥價設定
    • 藥價設定制度

第7章 基準等級

  • 地區的基準等級
    • 概要
  • 主要指標趨勢
    • 宏觀經濟指標
    • 醫療支出&基礎設施指標
    • 商業環境
    • 法律規章、臨床試驗環境

第8章 展望

  • 焦點從處方者轉變到醫療費支付者
  • 市場進入與產品的商品化策略

第9章 附錄

圖表

目錄
Product Code: GDHC013PSR

GlobalData's "PharmaSphere: North American Market Access Strategy" report provides a strategic analysis of the pharmaceutical market landscape in this geographic region, and the impact of the current and emerging market access strategies that the pharmaceutical industry is using for its for new and existing drugs. It discusses the regulatory requirements for pharmaceutical products in North American, key health insurance trends, recent government healthcare reforms, and general industry trends. It also describes the macroeconomic factors that impact the commercialization of new pharmaceutical products. Furthermore, it includes a geographic segmentation of the various markets in North America, including the US, Canada, and Mexico, providing an in-depth analysis of these markets' regulatory frameworks, healthcare systems, health insurance markets, key domestic players, and strategic outlook.

Highlights

Key Questions Answered

  • What are the main factors influencing market access in North America?
  • How do demographic trends impact market access in Canada and Mexico?
  • What are the important elements of the healthcare systems in the US, Canada, and Mexico?
  • How important is health technology assessment (HTA)? What are the key processes leading up to a successful HTA in North America?
  • What are the different pricing and reimbursement procedures adopted by regulators in North America?
  • How has recent healthcare reform legislation changed market access considerations from the perspective of regulators and pharmaceutical companies?
  • How have cost-containment pressures impacted the commercialization of new pharmaceutical products?

Reasons to buy

  • Identify the key decision makers in various countries in the North American region, including the US, Canada, and Mexico
  • Understand the key causes, concerns, drivers, and trends that characterize the market access process
  • Analyze the impact of recent healthcare reform legislation on market access procedures
  • Identify the key factors in the market access process, such as pricing, reimbursement, co-payments, discounts, and pharma economic guidelines
  • Understand the impact of macroeconomic factors, such as healthcare expenditures, foreign direct investment (FDI), and population demographics on the market access process

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Companies Mentioned
  • 2.3. Upcoming Reports
  • 2.4. Related Reports

3. Market Access Policy Evolution

  • 3.1. Key Concepts in Market Access
    • 3.1.1. Reference Pricing System
  • 3.2. Health Technology Assessments
    • 3.2.1. Use of Pharmacoeconomics

4. United States

  • 4.1. Pharmaceutical Market
    • 4.1.1. Market Size and Forecast
    • 4.1.2. Market Segments and Disease Areas
  • 4.2. Health Insurance Market
    • 4.2.1. Managed Care
    • 4.2.2. US Government-Sponsored Health Insurance Plans
    • 4.2.3. Children's Health Insurance Program
  • 4.3. Regulatory Landscape
    • 4.3.1. Implementation of the ACA
    • 4.3.2. Health Insurance Marketplace
  • 4.4. Drug Pricing
    • 4.4.1. Pricing Policies
    • 4.4.2. Types of Funding
  • 4.5. Reimbursement
    • 4.5.1. Academy of Managed Care Pharmacy Guidance Format
    • 4.5.2. Medicare Coverage Policies

5. Canada

  • 5.1. Pharmaceutical Market
    • 5.1.1. Market Size and Forecasts
    • 5.1.2. Market Segments and Disease Areas
  • 5.2. Health Insurance Market
    • 5.2.1. Public Insurance
    • 5.2.2. Private Insurance
  • 5.3. Regulatory Landscape
    • 5.3.1. Canada Health Act
    • 5.3.2. National Pharmaceuticals Strategy
  • 5.4. Pricing
    • 5.4.1. Pricing Policies
    • 5.4.2. Patented Drug Price Trends
  • 5.5. Reimbursement
    • 5.5.1. Reimbursement Policies

6. Mexico

  • 6.1. Pharmaceutical Market
    • 6.1.1. Market Size and Forecasts
    • 6.1.2. Market Segments and Disease Areas
  • 6.2. Health Insurance Market
    • 6.2.1. Public Insurance
    • 6.2.2. Private Insurance
  • 6.3. Regulatory Landscape
    • 6.3.1. COFEPRIS
  • 6.4. Pricing
    • 6.4.1. Pricing Policies

7. Benchmark Ratings

  • 7.1. Regional Benchmark Ratings
    • 7.1.1. Overview
  • 7.2. Key Parameter Trends
    • 7.2.1. Macroeconomic Parameters
    • 7.2.2. Healthcare Expenditures and Infrastruture Parameters
    • 7.2.3. Business Environment
    • 7.2.4. Regulatory and Clinical Trial Landscape

8. Outlook

  • 8.1. Shift in Focus from Prescriber to Payer
  • 8.2. Market Access Alters Product Commercialization Strategies

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Research Methodology
    • 9.3.1. Coverage
    • 9.3.2. Secondary Research
  • 9.4. About the Author
    • 9.4.1. Aparna Krishnan, Industry Analyst
    • 9.4.2. Global Head of Healthcare
  • 9.5. About the Industry Dynamics Team
  • 9.6. About GlobalData
  • 9.7. Disclosure Information
  • 9.8. Disclaimer

List of Tables

  • Table 1: 2012 AMCP Guidance Format
  • Table 2: Medicare Coverage: Parts A, B, C, and D
  • Table 3: PharmaCare Plans, 2011
  • Table 4: Annual Change (%) in PMPI, Canada, 2005-2012
  • Table 5: Change (%) in PMPI by Major Therapeutic Class, Canada, 2011-2012
  • Table 6: Levels of Therapeutic Improvement, 2012
  • Table 7: Benchmark Ratings for the North American Region

List of Figures

  • Figure 1: Historical Sales of Branded Biologics, 2008-2014 and Forecast to 2020
  • Figure 2: Major Disease Areas of Patented Drug Products (%), Canada
  • Figure 3: Annual GDP Growth (%), North America, 2010-2013
  • Figure 4: FDI Levels (%) of GDP, North America, 2010-2013
  • Figure 5: Unemployment Levels (%) of GDP, North America, 2010-2012
  • Figure 6: R&D Expenditures (%) of GDP, North America, 2010-2012
  • Figure 7: Healthcare Expenditures per Capita, North America, 2010-2012
  • Figure 8: Total Healthcare Expenditures (%) of GDP, North America, 2010-2012
  • Figure 9: Out-of-Pocket Healthcare Expenditures (%), North America, 2010-2012
  • Figure 10: Concentration (%) of the Geriatric Population, North America, 2010-2013
  • Figure 11: Governance Index, North America, 2010-2013
  • Figure 12: Ease of Doing Business Index, North America, 2013-2014
  • Figure 13: Intellectual Property Rights Index, North America, 2013-2014
Back to Top